In contrast, KM analysis of DFI showed a poor prognosis of DFI in patients with higher CKMT2 expression in CESC and HNSC, but a better prognosis in LIHC and PRAD (Fig. 6A–E). Here, CKMT2 is linked to prostate adenocarcinoma.